Parkinson's disease therapy: what lies ahead?

J Neural Transm (Vienna) · 2023 · PMC10199869 · PMID 37147404

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Prasinezumab (PRX002), a C-terminal antibody, missed its primary endpoint in the phase 2 trial (change of MDS-UPDRS I-III after 52 weeks; NCT03100149 ), yet showed a trend to slow decline in motor function (MDS-UPDRS part III).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.